Hsbc Holdings PLC Trims Stock Position in Charles River Laboratories International, Inc. $CRL

Hsbc Holdings PLC decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 25.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 62,084 shares of the medical research company’s stock after selling 20,876 shares during the period. Hsbc Holdings PLC’s holdings in Charles River Laboratories International were worth $12,401,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Charles River Laboratories International by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after buying an additional 47,432 shares during the period. Invesco Ltd. grew its position in Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares during the period. State Street Corp increased its stake in Charles River Laboratories International by 2.2% during the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after acquiring an additional 40,535 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Charles River Laboratories International by 27.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,442,224 shares of the medical research company’s stock worth $287,703,000 after acquiring an additional 311,319 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Charles River Laboratories International by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock valued at $254,186,000 after purchasing an additional 9,756 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.1%

CRL opened at $228.98 on Wednesday. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $236.62. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The business has a fifty day simple moving average of $183.96 and a 200-day simple moving average of $185.06. The firm has a market cap of $11.03 billion, a P/E ratio of -60.90, a P/E/G ratio of 2.64 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same quarter in the previous year, the business earned $2.34 EPS. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on CRL. Evercore reaffirmed an “outperform” rating and issued a $220.00 price target on shares of Charles River Laboratories International in a research note on Friday, May 8th. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Barclays increased their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $215.88.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the sale, the director directly owned 31,596 shares in the company, valued at $7,109,100. This represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.